Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (895)	9/8/1999 5:32:00 PM
From: Dr. John M. de Castro	Read Replies (2) \| Respond to of 1386

Cohort 3 mortality data encompasses both HU-211 treated subjects and placebo treated subjects. The blind has not been broken and no one knows who was treated and who wasn't. So a low mortality rate overall is interesting. But, it doesn't tell us that HU-211 is responsible. An alternative explanation for a lower mortality rate is that it could result from improved medical care for all TBI patients and both treated and control subjects thereby have lower mortality. Alternatively, the subject population may have less severe injuries (eg from the more widespread adoption of air bags etc.). There are other possibilities. But, I won't bore you by listing them. The bottom line is that it is nice to hear of lower mortality and its great for the patients. But, don't get too excited that its suggesting efficacy just yet. From the prior cohorts, IMHO HU-211 worked. So, I have every reason to believe that it is working in Cohort 3. But, the fact of overall lower mortality doesn't prove that just yet. Time will tell and we should know early next year. Best regards John de C